Oral Cancer: Navigating Trials and Innovations in Patient Care

The diagnostic odyssey

Oral cancer, particularly oral squamous cell carcinoma, presents a significant burden on patients and healthcare systems globally. The complexities surrounding diagnosis contribute to a prolonged and often frustrating journey for those affected. Symptoms may be subtle and easily overlooked, leading to late-stage diagnoses when treatment options become limited. The challenge lies not only in recognizing the signs early but also in identifying eligible patients for clinical trials that could offer new therapeutic avenues. With an estimated 54,540 new cases of oral cavity and oropharyngeal cancers expected in the United States alone in 2023, the demand for effective early detection strategies is paramount.

The trial landscape right now

Currently, our live trial registry indicates that there are 11 recruiting trials focused on oral cancer, spread across 12 sites in 4 countries. This includes a mix of 10 trials in various phases and one in Phase II. The leading sponsors of these trials are notable institutions such as National Taiwan University Hospital, which is involved in 4 trials, and Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, with 2 trials. Other prominent sponsors include M.D. Anderson Cancer Center, Case Comprehensive Cancer Center, and New York University.

Geographically, Taiwan leads with 5 trials, followed closely by the United States with 4, and China and Canada contributing 2 and 1, respectively. For instance, the trial NCT06130332 titled "Neoadjuvant Tirellizumab Combined With Chemotherapy for Early Oral Squamous Cell Carcinoma" is sponsored by Sun Yat-Sen Memorial Hospital and is currently being conducted in China. Another example, NCT06550050, explores the "Clinical and Molecular Features of Oral Premalignancy and Oral Cancer" and is sponsored by M.D. Anderson Cancer Center in the United States. This landscape highlights the ongoing efforts to advance treatment options and improve outcomes for patients diagnosed with oral cancer.

How we detect the match

To enhance patient eligibility identification for these trials, an innovative approach utilizing an HL7/FHIR + AI layer can be employed. This technology leverages existing clinical data to surface eligible patients without the need for manual chart reviews, streamlining the process significantly. By utilizing specific FHIR resources such as Condition, Observation, MedicationRequest, and DiagnosticReport, healthcare providers can efficiently identify patients who meet trial criteria based on their clinical history.

For example, signals from lab results, genetic markers, and ICD-10 codes can be integrated to form computable phenotypes that accurately represent patient profiles. This automated matching process not only increases the likelihood of finding eligible patients but also enhances the speed at which they can be enrolled in trials. By reducing the reliance on manual processes, healthcare systems can improve their operational efficiency and ensure that patients have timely access to potentially life-saving treatments.

Beyond the trial: better care

The integration of HL7/FHIR + AI does not only facilitate trial enrollment; it also plays a crucial role in improving overall patient care. By utilizing the same technology, healthcare providers can shorten the diagnostic odyssey for patients, ensuring that they receive the necessary care more promptly. Enhanced coordination among multidisciplinary teams becomes achievable, allowing for better monitoring of patient progress, treatment responses, and potential complications.

This interconnected approach fosters a holistic view of patient management, ensuring that even those who do not enroll in trials receive high-quality care tailored to their specific needs. It supports a seamless flow of information between providers and patients, ultimately leading to improved outcomes and patient satisfaction.

The takeaway

The landscape of oral cancer trials is evolving, with significant efforts underway to improve patient detection and care. By leveraging advanced technologies such as HL7/FHIR and AI, healthcare systems can facilitate better trial matching and enhance the overall patient experience. As we continue to navigate the complexities of oral cancer, these innovations hold the potential to transform the diagnostic and treatment journey for countless individuals.